Free Trial

Perrigo Q1 2024 Earnings Report

Perrigo logo
$27.91 +0.47 (+1.73%)
As of 03/11/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Perrigo EPS Results

Actual EPS
$0.29
Consensus EPS
$0.23
Beat/Miss
Beat by +$0.06
One Year Ago EPS
$0.45

Perrigo Revenue Results

Actual Revenue
$1.08 billion
Expected Revenue
$1.09 billion
Beat/Miss
Missed by -$11.02 million
YoY Revenue Growth
-8.40%

Perrigo Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Perrigo Earnings Headlines

This AI pick beats my 2016 Nvidia prediction
There’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech companies are all scrambling to build hundreds of new mega data centers to keep up with the demand for training and using new AI models. But that’s where the problem is. It doesn’t matter how many new data centers we build, we won’t be able to keep up with the insatiable demand… We can build thousands of them — even millions.
Perrigo Company plc (PRGO) Stock Forecasts
Perrigo rises 16.6%
Perrigo Company plc (PRGO) 2025 Investor Day (Transcript)
See More Perrigo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Perrigo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perrigo and other key companies, straight to your email.

About Perrigo

Perrigo (NYSE:PRGO) provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

View Perrigo Profile

More Earnings Resources from MarketBeat